MA71240A - Formulation d'oxytocine - Google Patents

Formulation d'oxytocine

Info

Publication number
MA71240A
MA71240A MA71240A MA71240A MA71240A MA 71240 A MA71240 A MA 71240A MA 71240 A MA71240 A MA 71240A MA 71240 A MA71240 A MA 71240A MA 71240 A MA71240 A MA 71240A
Authority
MA
Morocco
Prior art keywords
oxytocin formulation
oxytocin
formulation
Prior art date
Application number
MA71240A
Other languages
English (en)
Inventor
Ivona JASPRICA
Marcel LAGEDROSTE
Original Assignee
Hikma Pharmaceuticals Usa Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hikma Pharmaceuticals Usa Inc. filed Critical Hikma Pharmaceuticals Usa Inc.
Publication of MA71240A publication Critical patent/MA71240A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA71240A 2022-06-24 2023-06-23 Formulation d'oxytocine MA71240A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263355195P 2022-06-24 2022-06-24
US202363489486P 2023-03-10 2023-03-10
PCT/EP2023/067134 WO2023247760A1 (fr) 2022-06-24 2023-06-23 Formulation d'oxytocine
EP23736000.3A EP4543415A1 (fr) 2022-06-24 2023-06-23 Formulation d'oxytocine

Publications (1)

Publication Number Publication Date
MA71240A true MA71240A (fr) 2025-04-30

Family

ID=87067005

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71240A MA71240A (fr) 2022-06-24 2023-06-23 Formulation d'oxytocine

Country Status (9)

Country Link
US (1) US20240139278A1 (fr)
EP (1) EP4543415A1 (fr)
JP (1) JP2025522571A (fr)
AU (1) AU2023288088A1 (fr)
CA (1) CA3259933A1 (fr)
MA (1) MA71240A (fr)
TW (1) TW202412832A (fr)
UY (1) UY40329A (fr)
WO (1) WO2023247760A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025235701A1 (fr) * 2024-05-08 2025-11-13 Amneal Pharmaceuticals Llc Compositions d'oxytocine prêtes à infuser

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001026642A2 (fr) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Procedes et compositions pour le traitement de troubles de comportement neurologique
EP2710136A4 (fr) * 2011-05-17 2015-01-21 Moderna Therapeutics Inc Acides nucléiques manipulés et leurs procédés d'utilisation pour des vertébrés non humains
CN108236716A (zh) * 2016-12-23 2018-07-03 深圳翰宇药业股份有限公司 一种含缩宫素类似物的药物组合物及其制备方法和用途
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
EP4288078A4 (fr) * 2021-02-03 2024-12-11 Sun Pharmaceutical Industries Ltd Forme pharmaceutique prête à perfuser d'oxytocine

Also Published As

Publication number Publication date
JP2025522571A (ja) 2025-07-15
US20240139278A1 (en) 2024-05-02
CA3259933A1 (fr) 2023-12-28
TW202412832A (zh) 2024-04-01
UY40329A (es) 2024-01-15
WO2023247760A1 (fr) 2023-12-28
EP4543415A1 (fr) 2025-04-30
AU2023288088A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
EP4319764A4 (fr) Thionucléosides en guise d'agents antiviraux
UA42295S (uk) Комп'ютер
UA42369S (uk) Комп'ютер
EP3943417A4 (fr) Robot d'entreposage
EP4267598A4 (fr) Nouvelles protéines inhibitrices d'insectes
EP3887402A4 (fr) Plaquettes utilisées comme agents d'administration
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
EP3914608A4 (fr) Nouvelles protéines d'inhibition des insectes
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP4023292A4 (fr) Formulation d'injection
EP4203920A4 (fr) Nanosolutions d'ozone liposomales
MA54052A (fr) Formulation d'anticorps
EP4188544A4 (fr) Formulations d'anticorps anti-connexine
EP3820980A4 (fr) Compositions d'esterquats
MA54139A (fr) Formulation d'anticorps
EP3982415A4 (fr) Panneau d'affichage
EP3986415A4 (fr) Formulations d'ibogaïne
EP3919581A4 (fr) Composition d'agent adhésif à base d'uréthane
EP3919579A4 (fr) Composition adhésive à base d'uréthane
EP3952758A4 (fr) Guide d'ostéotomie
MA71240A (fr) Formulation d'oxytocine
EP3773574A4 (fr) Formulations d'amlodipine
EP4081692A4 (fr) Structures d'angle
EP4490843A4 (fr) Techniques d'évitement d'intermodulation passive
EP4284362A4 (fr) Préparations